Quoin Pharmaceuticals, Ltd. — Form 10-Q
Filed August 14, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Dr. Michael Myers (CEO) and Sally Lawlor (CFO) issued routine Sarbanes-Oxley Section 302 and 906 certifications dated August 14, 2026, for the quarter ended June 30, 2026. Both officers certified the accuracy of financial statements, effectiveness of disclosure controls, and compliance with SEC reporting requirements. No material changes, weaknesses, or fraud disclosures were noted.
Why this rating
Purely boilerplate SOX compliance documentation; routine quarterly filing requirement with no business, financial, or operational substance disclosed.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.